The BioCentury Show
Duración total:
20 h 04 min
Ep. 87 – Korea’s Biotech Playbook: Orum CEO SJ Lee on Going Global and Creating Novel Therapies
The BioCentury Show
27:41
Ep. 86 – Macrophages, ASCO & Clever-1: Faron CEO Juho Jalkanen on Bexmarilimab’s Promise
The BioCentury Show
10:22
Ep. 85 - Stifel’s Opler on Trump 2.0's FDA & the Capital Markets
The BioCentury Show
32:39
Ep. 84 – Leadership Amid Turmoil: Moonlake CEO Jorge Santos Da Silva
The BioCentury Show
29:19
Ep. 83 – Europe’s Biotech Moment: Jérôme van Biervliet on Turning Uncertainty into Opportunity
The BioCentury Show
31:54
Ep. 82 – Act Now or Fall Behind: Michelle Rozo on Biotech’s National Security Stakes
The BioCentury Show
31:01
Ep. 81 - Data-Driven Growth: Immunocore CEO Bahija Jallal on Expanding TCR Therapies
The BioCentury Show
30:52
Ep. 80 - Vertex’s Winning Formula: Altshuler on Choosing the Next Breakthroughs
The BioCentury Show
32:26
Ep. 79 - BNP Paribas’ Moneer on Biotech’s Bull Case: M&A, PE, and Market Recovery
The BioCentury Show
29:33
Ep. 78 - Biotech’s New Normal: SR One’s Simeon George on Adapting to Market Constraints
The BioCentury Show
31:04
Ep. 77 - AI’s Next Leap: Foresite Labs’ Vik Bajaj on Predictive Biology
The BioCentury Show
35:29
Ep. 76 - FDA Inflection Point: Steve Usdin on Biopharma during Trump 2.0
The BioCentury Show
34:01
Ep. 75 - PBMs, IRA, RFK Jr: A Conversation With Rep. Jake Auchincloss
The BioCentury Show
36:04
Ep. 74 - Chris Bardon on Biotech’s Recovery: Valuations, Obesity Drugs, and M&A
The BioCentury Show
34:03
Ep. 73 - Resilience and the CEO’s Paradox: Aoife Brennan on Leading in Biotech
The BioCentury Show
32:12
Ep. 72 - Outlook for Biotech M&A and Financing: Sidley's Robert Darwin
The BioCentury Show
35:54
Ep. 71 - Pazdur Unplugged: FDA Director Richard Pazdur on the Past, Future of Cancer Treatments
The BioCentury Show
41:44
Ep. 70 - Trends in Global Biopharma Deals: Lazard’s Kingston and Raine
The BioCentury Show
33:56
Ep. 69 - Lee Fleisher: An Insider’s Account of CMS’s Alzheimer’s Coverage Decisions
The BioCentury Show
34:36
Ep. 68 - Inside BeiGene: CEO John Oyler on Owning the Drug Development Process
The BioCentury Show
35:08
Ep 67 - AAM's Craig Burton on Opportunities, Challenges of U.S. Biosimilars Market
The BioCentury Show
28:51
Popular Episode - Bob Nelsen on AI, China and the IRA
The BioCentury Show
35:33
Ep. 66 - Jane Grogan on Building Biogen’s Growth Engine
The BioCentury Show
32:23
Ep. 65 - Astellas' Claus Zieler: Global Launches with Local Impact
The BioCentury Show
32:27
Ep. 64 - NPC CEO John O’Brien: Why America Needs an Honest Conversation About Drug Pricing
The BioCentury Show
33:36
Ep. 63 - Day One's Jeremy Bender: Building Pediatric Oncology from the Ground Up
The BioCentury Show
32:27
Ep. 62 - Rick Bright: Navigating the Avian Flu Threat
The BioCentury Show
40:22
Ep. 61 - Vas Narasimhan: How New Data Fit Novartis’ Growth Plan
The BioCentury Show
32:11
Ep. 60 - JMM John Maraganore: A higher bar for investment is a credit to biotech
The BioCentury Show
36:00
Ep. 59 - Derek Lowe Unplugged: AI; Biosecure; FDA, Abortion & SCOTUS; and more
The BioCentury Show
32:09
Ep. 57 - BMS's Robert Plenge: Causal biology is the North Star of R&D
The BioCentury Show
31:17
Ep. 58 - Ysios' Karen Wagner: How Europe's Biotechs Can Rise Above the Noise
The BioCentury Show
30:54
Ep. 53 - Bob Nelsen on AI, China and the IRA
The BioCentury Show
35:26
Ep. 54 - Arthur Caplan: Lessons From a Compassionate Use Firestorm
The BioCentury Show
30:52
Ep. 55 - Bruce Booth: Biotech Benefiting from Belt-Tightening
The BioCentury Show
32:10
Ep. 56 - BIO’s John Crowley on the Biosecure Act
The BioCentury Show
36:55
Ep. 52 - Khoo Shih on Scaling Singapore Biotech
The BioCentury Show
31:27
